Taking a Different Approach to Better

rEVO Biologics, Inc. is a rare disease company delivering on the promise of recombinant medicine. By eliminating the barriers of limited access and production, we bring therapeutics to the market that make a real difference in the lives of patients.
Our track record of commercialization success started in the area of hereditary antithrombin deficiency with the strong sales growth and significant market share gains of our first product, ATryn® Antithrombin (Recombinant).  And today we're growing even further with more products, as well as new indications for ATryn. Our ongoing clinical trials are opening access to even larger markets in underserved therapeutic classes with high patient needs. 
Our groundbreaking approach to therapeutics enables expanded access to innovative therapies for the treatment of hematology, oncology, autoimmune and genetic diseases. The results are nothing short of remarkable. Better therapeutics, better economics, better outcomes. rEVO Biologics is committed to taking a different approach to better.

Latest News

March 31, 2014 Company Announces FDA Acceptance of Investigational New Drug Application to Initiate PRESERVE-1— enrollment to begin mid-2014     rEVO Biologics Inc., a subsidiary of... Read More >
February 25, 2014 Company Submits Investigational New Drug (IND) Application for the Treatment of Preeclampsia in Pregnant Women to Prolong Gestation and Decrease Fetal and Neonatal Morbidity and Mortality... Read More >